Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer's pathologies

Translational Psychiatry

Volumn 5, Issue 2, 2015, Pages

  Malishkevich, A ^a   Amram, N ^a   Hacohen Kleiman, G ^a   Magen, I ^a   Giladi, E ^a   Gozes, I ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE PROTEIN; INITIATION FACTOR 4E; PROTEIN; UNCLASSIFIED DRUG; ADNP PROTEIN, MOUSE; APOLIPOPROTEIN E; HOMEODOMAIN PROTEIN; MESSENGER RNA; NERVE PROTEIN;

ALZHEIMER DISEASE; ARTICLE; AUTISM; BINDING SITE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENETIC RISK; HABITUATION; HAPLOINSUFFICIENCY; HIPPOCAMPUS; IMMUNOPRECIPITATION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; OLFACTORY MEMORY; PATTERN RECOGNITION; PROTEIN BINDING; PROTEIN EXPRESSION; SEX DIFFERENCE; SMELLING; SOCIAL INTERACTION; SOCIAL RECOGNITION TEST; ANIMAL; ANIMAL BEHAVIOR; GENE EXPRESSION PROFILING; GENETICS; HETEROZYGOTE; HUMAN; MEMORY; METABOLISM; RECOGNITION; SOCIAL BEHAVIOR;

ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; GENE EXPRESSION PROFILING; HETEROZYGOTE; HIPPOCAMPUS; HOMEODOMAIN PROTEINS; HUMANS; MALE; MEMORY; MICE; NERVE TISSUE PROTEINS; RECOGNITION (PSYCHOLOGY); RNA, MESSENGER; SEX FACTORS; SOCIAL BEHAVIOR;

EID: 84927754004     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.138     Document Type: Article

References (63)

1. Maenner MJ, Rice CE, Arneson CL, Cunniff C, Schieve LA, Carpenter LA et al. Potential impact of DSM-5 criteria on autism spectrum disorder prevalence estimates. JAMA Psychiatry 2014; 71: 292-300.
2. Gillberg C, Billstedt E. Autism and Asperger syndrome: coexistence with other clinical disorders. Acta Psychiatr Scand 2000; 102: 321-330.
3. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466: 368-372.
4. Talkowski ME, Rosenfeld JA, Blumenthal I, Pillalamarri V, Chiang C, Heilbut A et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 2012; 149: 525-537.
5. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol 2014; 6: 37-48.
6. Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet 2014; 46: 380-384.
7. O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012; 338: 1619-1622.
8. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012; 485: 246-250.
9. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 1999; 72: 1283-1293.
10. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem 2001; 276: 708-714.
11. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM et al. Activitydependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 2003; 144: 83-90.
12. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 2007; 323: 438-449.
13. Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol 2007; 303: 814-824.
14. Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One 2012; 7: e51458.
15. Quraishe S, Cowan CM, Mudher A. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol Psychiatry 2013; 18: 834-842.
16. Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009; 34: 381-388.
17. Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y et al. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). J Alzheimers Dis 2014; 40: S23-S36.
18. Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S. NAP alphaaminoisobutyric acid (IsoNAP). J Mol Neurosci 2014; 52: 1-9.
19. Oz S, Kapitansky O, Ivashco-Pachima Y, Malishkevich A, Giladi E, Skalka N et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry 2014; 19: 1115-1124.
20. Garbern JY, Neumann M, Trojanowski JQ, Lee VM, Feldman G, Norris JW et al. A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. Brain 2010; 133: 1391-1402.
21. Latapy C, Rioux V, Guitton MJ, Beaulieu JM. Selective deletion of forebrain glycogen synthase kinase 3beta reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci 2012; 367: 2460-2474.
22. Mukaetova-Ladinska EB, Arnold H, Jaros E, Perry R, Perry E. Depletion of MAP2 expression and laminar cytoarchitectonic changes in dorsolateral prefrontal cortex in adult autistic individuals. Neuropathol Appl Neurobiol 2004; 30: 615-623.
23. Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci 2008; 35: 127-141.
24. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR. Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 2005; 25: 225-238.
25. Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry 2013.
26. Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease. Biochim Biophys Acta 2014; 1842: 7-21.
27. Di Nardo A, Wertz MH, Kwiatkowski E, Tsai PT, Leech JD, Greene-Colozzi E et al. Neuronal Tsc1/2 complex controls autophagy through AMPK dependent regulation of ULK1. Hum Mol Genet 2014; 23: 3865-3874.
28. Dere E, Dahm L, Lu D, Hammerschmidt K, Ju A, Tantra M et al. Heterozygous ambra1 deficiency in mice: a genetic trait with autism-like behavior restricted to the female gender. Front Behav Neurosci 2014; 8: 181.
29. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 2014; 506: 179-184.
30. Dresner E, Agam G, Gozes I. Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol 2011; 21: 355-361.
31. Okada K, Hashimoto K, Iwata Y, Nakamura K, Tsujii M, Tsuchiya KJ et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 187-190.
32. Maekawa M, Iwayama Y, Nakamura K, Sato M, Toyota T, Ohnishi T et al. A novel missense mutation (Leu46Val) of PAX6 found in an autistic patient. Neurosci Lett 2009; 462: 267-271.
33. Shiryaev N, Pikman R, Giladi E, Gozes I. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des 2011; 17: 2603-2612.
34. Braitch M, Kawabe K, Nyirenda M, Gilles LJ, Robins RA, Gran B et al. Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Neuroimmunomodulation 2009; 17: 120-125.
35. Yang MH, Yang YH, Lu CY, Jong SB, Chen LJ, Lin YF et al. Activity-dependent neuroprotector homeobox protein: a candidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J Proteomics 2012; 75: 3617-3629.
36. Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE et al. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett 2005; 373: 73-78.
37. Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004; 361: 128-131.
38. Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubuledeficient model of schizophrenia. Peptides 2010; 31: 1368-1373.
39. McFarlane HG, Kusek GK, Yang M, Phoenix JL, Bolivar VJ, Crawley JN et al. Autismlike behavioral phenotypes in BTBR T+tf/J mice. Genes Brain Behav 2008; 7: 152-163.
40. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-153.
41. Bernstein J, Shefler I, Elroy-Stein O. The translational repression mediated by the platelet-derived growth factor 2/c-sis mRNA leader is relieved during megakaryocytic differentiation. J Biol Chem 1995; 270: 10559-10565.
42. Gkogkas CG, Khoutorsky A, Ran I, Rampakakis E, Nevarko T, Weatherill DB et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 2013; 493: 371-377.
43. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3: 1101-1108.
44. Gosselin P, Martineau Y, Morales J, Czjzek M, Glippa V, Gauffeny I et al. Tracking a refined eIF4E-binding motif reveals Angel1 as a new partner of eIF4E. Nucleic Acids Res 2013; 41: 7783-7792.
45. Dresner E, Malishkevich A, Arviv C, Leibman BS, Alon S, Ofir R et al. Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem 2012; 287: 40173-40185.
46. Yu J, He X, Yao D, Li Z, Li H, Zhao Z et al. A sex-specific association of common variants of neuroligin genes (NLGN3 and NLGN4X) with autism spectrum disorders in a Chinese Han cohort. Behav Brain Funct 2011; 7: 13.
47. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem 2007; 282: 34448-34456.
48. Garcia-Pedrero JM, Kiskinis E, Parker MG, Belandia B. The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells. J Biol Chem 2006; 281: 22656-22664.
49. Aboonq MS, Vasiliou SA, Haddley K, Quinn JP, Bubb VJ. Activity-dependent neuroprotective protein modulates its own gene expression. J Mol Neurosci 2012; 46: 33-39.
50. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 2008; 29: 1725-1733.
51. Li X, Zhu C, Tu WH, Yang N, Qin H, Sun Z et al. ZMIZ1 preferably enhances the transcriptional activity of androgen receptor with short polyglutamine tract. PLoS One 2011; 6: e25040.
52. Gozes I, Cronin BL, Moskowitz MA. Protein synthesis in rat brain microvessels decreases with aging. J Neurochem 1981; 36: 1311-1315.
53. Tavernarakis N. Ageing and the regulation of protein synthesis: a balancing act Trends Cell Biol 2008; 18: 228-235.
54. Schirer Y, Malishkevich A, Ophir Y, Lewis J, Giladi E, Gozes I et al. Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. PLoS One 2014; 9: e87383.
55. Joshi S, Platanias LC. Mnk kinase pathway: cellular functions and biological outcomes. World J Biol Chem 2014; 5: 321-333.
56. Dinamarca MC, Weinstein D, Monasterio O, Inestrosa NC. The synaptic protein neuroligin-1 interacts with the amyloid beta-peptide. Is there a role in Alzheimer's disease Biochemistry 2011; 50: 8127-8137.
57. Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y et al. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). J Alzheimers Dis 2014; 40: S23-S36.
58. Gozes I, Schirer Y, Oz S. Activity-dependent neuroprotective protein (ADNP) is regulated in the brains of mouse models of human tauopathies: toward davunetide replacement therapy. Alzheimers Dement 2010; 6: S578-S579.
59. Gozes I. Davunetide (NAP) pharmacology: neuroprotection and tau. In: Martinez, A (ed). Emerging Drugs and Targets for Alzheimer's Disease. Royal Society of Chemistry: Cambridge, UK, 2010, 108-128.
60. Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D et al. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr Alzheimer Res 2009; 6: 455-460.
61. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014; 13: 676-685.
62. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2012; 136: 25-31.
63. Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology 2013; 38: 1245-1252.